Weekly round-up: A fund aiming to free a whopping $30bn of trapped biotech capital, strategic hires, plus a new episode of ‘Dealmakers’ on Optimum TV

/in

Renée Aguiar-Lucander appointed Chief Executive Officer of Hansa Biopharma   Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB where she successfully led the company through a dual listing on NASDAQ in both Sweden […]

Read more

Hot topic: What does the future hold for vaccines?

/in

Vaccines are not a new medical technology. It is almost 230 years since Edward Jenner, a British doctor, inoculated eight-year-old James Phipps with fluid from a cowpox sore in a successful attempt to prove it would protect the boy from the scourge of the time, smallpox. So, it is perhaps surprising that scepticism and downright […]

Read more

Will Trump hit foreign pharma companies with tariffs?

/in

Well, the last fortnight’s certainly been a rollercoaster. Ever since President Trump announced his plans for sweeping tariffs on foreign goods entering the US on Thursday April 3, markets have hardly been able to catch their collective breath. First there was the initial shock, at which point stocks tanked, before lurching up and down, and […]

Read more

Weekly round-up: Optimum clients are rising to the top

/in

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council Xeltis announces that it has successfully passed the evaluation phase of the 2025 European Innovation Council (‘EIC’) STEP Scale-Up call program, and is set to secure a €10 million equity investment from the EIC, subject to an award decision by the European Commission […]

Read more

Hot topic: Betting big on AI-based drug discovery

/in

It’s no secret that 2025 is turning into a tricky year for life science companies looking to raise cash. Political and economic uncertainty has fed through into  a ‘risk-off’ environment.  So, when DeepMind spin-out Isomorphic Labs, a London-based AI drug development company, announced last week (March 31) that it had pocketed a huge $600 million […]

Read more